MR PREDICTS决策工具的验证与更新:预测缺血性卒中结局与血管内治疗获益
研究基于HERMES六项随机对照试验的1242例患者验证MR PREDICTS模型,并用MR CLEAN登记3156例患者更新模型。功能独立(mRS 0–2)的C统计量在HERMES为0.74,更新后在登记中为0.80。常规治疗患者的中位预测获益为10.3%,预测获益极低者功能独立率低。
要点
- MR PREDICTS可预测3个月功能独立及EVT治疗获益。
- 更新模型在登记队列中区分度C统计量达0.80。
- 6小时内到达可开展EVT中心的患者多数应直接治疗。
核心结论
- 因EVT疗效显著且潜在伤害小,6小时内到达可开展EVT中心的多数患者应治疗,不必拘泥于临床特征。
- MR PREDICTS可在治疗指征不确定、资源有限或转运前辅助临床判断。
研究设计与样本
- 使用HERMES协作6项随机对照试验的个体患者数据(1242例,EVT组633例,对照组609例)外部验证原始模型。
- 更新模型后用观察性MR CLEAN登记3156例(均在6.5小时内接受EVT)进行二次验证。
主要发现
- 功能独立(mRS 0–2)的C统计量在HERMES为0.74(95%CI 0.72–0.77),模型更新后在登记为0.80(95%CI 0.78–0.82)。
- 登记中常规治疗患者的中位预测治疗获益为10.3%(四分位距5.8%–14.4%)。
- 预测治疗获益<1%者(135/3156,4.3%)功能独立率低,且与再灌注状态无关,提示可能无治疗获益。
关键数值与推荐
- 主要结局为卒中后3个月功能独立,定义为mRS评分0–2。
- 治疗获益定义为接受与不接受EVT时功能独立概率之差。
临床怎么用
- 更新模型已在线提供(www.mrpredicts.com)供临床医生和研究者使用。
- 可在治疗指征不确定、资源有限或患者拟转运至可开展EVT中心前使用MR PREDICTS支持临床判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Benefit of early endovascular treatment (EVT) for ischemic stroke varies considerably among patients. The MR PREDICTS decision tool, derived from MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), predicts outcome and treatment benefit based on baseline characteristics. Our aim was to externally validate and update MR PREDICTS with data from international trials and daily clinical practice. METHODS: We used individual patient data from 6 randomized controlled trials within the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration to validate the original model. Then, we updated the model and performed a second validation with data from the observational MR CLEAN Registry. Primary outcome was functional independence (defined as modified Rankin Scale score 0–2) 3 months after stroke. Treatment benefit was defined as the difference between the probability of functional independence with and without EVT. Discriminative performance was evaluated using a concordance (C) statistic. RESULTS: We included 1242 patients from HERMES (633 assigned to EVT, 609 assigned to control) and 3156 patients from the MR CLEAN Registry (all of whom underwent EVT within 6.5 hours). The C-statistic for functional independence was 0.74 (95% CI, 0.72–0.77) in HERMES and, after model updating, 0.80 (0.78–0.82) in the Registry. Median predicted treatment benefit of routinely treated patients (Registry) was 10.3% (interquartile range, 5.8%–14.4%). Patients with low (<1%) predicted treatment benefit (n=135/3156 [4.3%]) had low rates of functional independence, irrespective of reperfusion status, suggesting potential absence of treatment benefit. The updated model was made available online for clinicians and researchers at www.mrpredicts.com. CONCLUSIONS: Because of the substantial treatment effect and small potential harm of EVT, most patients arriving within 6 hours at an endovascular-capable center should be treated regardless of their clinical characteristics. MR PREDICTS can be used to support clinical judgement when there is uncertainty about the treatment indication, when resources are limited, or before a patient is to be transferred to an endovascular-capable center.
引用
- Venema E, Roozenbeek B, Mulder MJHL, et al. Prediction of Outcome and Endovascular Treatment Benefit: Validation and Update of the MR PREDICTS Decision Tool. Stroke. 2021. PMID: 34266308. doi:10.1161/STROKEAHA.120.032935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。